What's on the Horizon in Atopic Dermatitis? A Focus on OX40-OX40 Ligand-Targeted Therapies episode artwork

EPISODE · Jun 26, 2024 · 29 MIN

What's on the Horizon in Atopic Dermatitis? A Focus on OX40-OX40 Ligand-Targeted Therapies

from Keeping Current CME

Did you know that targeting the OX40-OX40 ligand (OX40-OX40L) pathway may lead to long-term remission in atopic dermatitis (AD)? Credit available for this activity expires: 6/26/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001214?ecd=bdc_podcast_libsyn_mscpedu

Episode metadata supplied by the publisher feed · Published Jun 26, 2024

Embed this episode

NOW PLAYING

What's on the Horizon in Atopic Dermatitis? A Focus on OX40-OX40 Ligand-Targeted Therapies

0:00 29:15

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Keeping Current CME?

This episode is 29 minutes long.

When was this Keeping Current CME episode published?

This episode was published on June 26, 2024.

Can I download this Keeping Current CME episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!